HealthBeacon PLC HealthBeacon - HBCN - Directorate Change

Healthbeacon

02/12/2022 12:03

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221202:nRSB4627Ia&default-theme=true

RNS Number : 4627I  HealthBeacon PLC  02 December 2022

Directorate change - Chief Financial Officer

 

HealthBeacon plc ("HealthBeacon" or "the Company"), a leader in devices and
software to manage critical and chronic medications, today announces that,
Laurence Flavin, Chief Financial Officer, has informed the Board of his
intention to leave the Company. Laurence will step down as Executive
Director, Chief Financial Officer and Company Secretary of HealthBeacon within
the next six months.

 

A process to appoint a successor is now underway in line with Board succession
planning and Laurence will work with the Chief Executive and the Board to
ensure an orderly transition.

 

Jim Joyce, Co-Founder and Chief Executive of HealthBeacon, commented:
"Laurence has been a committed and professional colleague and I am very
grateful to him for the significant contribution he has made to the business
during his tenure. Laurence was instrumental in our successful IPO process
last year and has built an excellent finance team that continues to serve the
Company very well. I wish Laurence every success and look forward to
continuing to work him during this transition period."

 

Robert Garber, Chairman of HealthBeacon, said: "I would like to thank Laurence
for his dedication to HealthBeacon during his time with the Company and wish
him success in the future. The Board has now moved to commence a search
process to identify and appoint a successor to lead the strong finance team at
HealthBeacon as the Company pursues its next phase of growth."

 

Laurence Flavin said: "I'd like to thank Jim, the Board and all my colleagues
at HealthBeacon for the rewarding and fulfilling time I spent with the
Company, and I wish them continued success in the future."

 

 

 Enquiries:
 HealthBeacon:                                    Investor.Relations@HealthBeacon.com

                                                (mailto:Investor.Relations@HealthBeacon.com)
 Jim Joyce

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Cathal Barry                                     +353 (0) 87 227 9281
 Paul Clifford                                    +353 (0) 87 327 2161

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Wave which
integrates with its existing technology. The Company operates across Europe,
North America and the United Kingdom and employs more than 70 people and has
obtained more than 30 design and utility patents. The Company's mission is to
become the world's leading digital therapeutics platform for patients managing
medications in the home.

 

Ends

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEFLFELFALFIIF